Andrew Moreno

DocwireNews

Researchers have performed statistical analysis of data from clinical trials in higher-risk myelodysplastic syndromes (MDS) to see if any relationships exist between outcome measures in this disease. They presented their findings at the 66th American Society of Hematology Annual Meeting &amp; Exposition in San Diego, California.
The investigative team was from the US Food and Drug Administration (FDA) in Silver Spring, Maryland.
The analysis included nine randomized, controlled, multicenter trials submitted to the FDA as part of New Drug Applications and Investigational New Drug Applications for MDS between 2000 and 2024. They had a combined patient population of 2,053 patients, which had a median age of 71 years, was 66% male, and 75% White. Two of the trials lacked active controls.
Of the seven studies with active controls, the investigators performed a trial-level meta-analysis of OS versus CR and OS versus CR plus partial response (PR). Weighted linear regression analysis found the association between OS and CR and between OS and CR plus PR to be weak, with coefficients of determination of 0.40 and 0.33, respectively.
Across all trials, the investigators calculated a moderate association between OS and EFS, with a coefficient of determination of 0.82. At the patient level, they also found that patients who achieved a response of CR had better OS compared with those who had a PR response, a hematologic improvement response, or no response, with hazard ratios of 0.70, 0.56, and 0.33, respectively.
The investigators noted that “[o]ur results are limited by the small number of trials, lack of an active comparator in two trials, and non-standardized response criteria across trials.”
They concluded that “[complete response (CR)] remains the response endpoint associated with greatest long-term benefit and that [event-free survival (EFS)], as defined, is not an established surrogate for [overall survival (OS)], but is worthy of further study.”
Reference
Kim N, Wang X, Bulatao I, et al. Response rate, event-free survival (EFS), and overall survival in higher-risk myelodysplastic syndromes (MDS): U.S. Food and Drug Administration (FDA) trial-level and patient-level analyses. Abstract #1829. Presented at the 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.

Emily Menendez

AI-Powered System Predicts Genetic Alterations in Patients With iCCA

Bile Duct Cancer

Campylobacter Presence in CRC Found to Accelerate Tumor Metastasis

Colorectal Cancer

Laura Litwin

How Bone Metastasis Impacts NSCLC Outcomes With Immune Checkpoint Inhibitors

Non-Small Cell Lung Cancer

Latest News

Higher-Risk MDS Trials Analysis: Complete Response is Most Relevant Outcome Measure

ASH 2024

US FDA researchers analyzed randomized, controlled, multicenter MDS trials for connections between OS, EFS, CR, and PR.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe